AI Summary Mavyret (glecaprevir/pibrentasvir) is a pan-genotypic, interferon-free direct-acting antiviral usually taken for 8 to 12 weeks that helps most hepatitis C patients reach sustained virologic response (SVR), or cure.
Medically reviewed.
Mavyret (glecaprevir/pibrentasvir) is an oral, fixed-dose combination direct-acting antiviral (DAA) medication used to treat chronic hepatitis C virus (HCV) infection. It combines two antiviral agents — glecaprevir and pibrentasvir — that work together to stop the virus from replicating. Mavyret is approved for HCV genotypes 1 through 6, making it a pan-genotypic treatment option. It does not require interferon or ribavirin, and most people complete treatment in 8 weeks. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Mavyret's role in hepatitis C treatment — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Mavyret fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT MAVYRET TREATMENT
Mavyret is a prescription medicine that combines two direct-acting antivirals (DAAs): glecaprevir and pibrentasvir. It is used to treat chronic hepatitis C virus (HCV) infection.
Mavyret works by blocking two different proteins the hepatitis C virus needs to replicate. Glecaprevir inhibits the HCV NS3/4A protease, and pibrentasvir inhibits the HCV NS5A protein. Together, they stop viral replication at multiple stages, helping rapidly reduce the amount of virus in the blood.
Mavyret is approved for hepatitis C genotypes 1 through 6, making it a pan-genotypic treatment option. It is an interferon-free and ribavirin-free regimen, which means it avoids some of the side effects associated with older hepatitis C therapies. Most people take Mavyret for 8 weeks, though your healthcare provider may extend treatment to 12 weeks depending on your genotype, prior treatment history, or whether you have cirrhosis, and will monitor you with tests such as Hepatitis C Testing and Liver Function Tests (LFTs).
WHO MAVYRET MAY BE SUITABLE FOR
Eligibility for Mavyret depends on your hepatitis C genotype, treatment history, liver condition, and overall health. Mavyret may be prescribed if you have chronic HCV infection requiring DAA therapy, an HCV genotype from 1 through 6, and a need for a short-course, interferon-free, ribavirin-free regimen. It may also be considered for some patients with severe renal impairment.
Some people are not eligible for hepatitis C treatment. This can include people who have clinically decompensated liver cirrhosis, are pregnant or wish to become pregnant, are addicted to alcohol or drugs, have significant neuropsychiatric syndromes, or have active autoimmune disease. Your healthcare provider will also review your current medications, since some drugs interact with Mavyret.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Mavyret. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Mavyret may be considered for adults with the following conditions or treatment goals:
Before recommending Mavyret, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW MAVYRET CAN HELP YOUR LIVER
Mavyret combines two direct-acting antivirals that block the hepatitis C virus at different points in its life cycle. Glecaprevir inhibits the HCV NS3/4A protease, which blocks the processing of viral proteins the virus needs to replicate. Pibrentasvir inhibits the HCV NS5A protein, which prevents viral replication and assembly.
Together, these two mechanisms rapidly reduce the amount of hepatitis C virus circulating in the blood. For most patients, this leads to sustained virologic response (SVR) — meaning the virus remains undetectable in the blood 12 weeks after finishing treatment. SVR is considered a cure for hepatitis C.
Mavyret is not used to manage symptoms alone — it is a curative, time-limited course of therapy. Your healthcare provider will monitor your response with tests such as HCV RNA levels and Liver Function Tests (LFTs) throughout treatment.
LIVER BENEFITS
Glecaprevir inhibits the HCV NS3/4A protease, blocking the processing of viral proteins the hepatitis C virus needs to replicate.
Pibrentasvir inhibits the HCV NS5A protein, preventing the virus from replicating and assembling new viral particles.
Together, glecaprevir and pibrentasvir stop viral replication at multiple stages, rapidly lowering the amount of hepatitis C virus in the blood.
Mavyret helps most patients achieve sustained virologic response (SVR), meaning the virus becomes undetectable and stays undetectable — considered a cure for hepatitis C.
Mavyret works by blocking hepatitis C at two different stages of its life cycle, helping most patients reach a cure (SVR). It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Mavyret is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions about your specific dose.
The typical dose is 3 tablets once daily with food. Your healthcare provider determines the exact dose and duration for you.
Take Mavyret at the same time each day with food, which improves how well the medication is absorbed. Always use it exactly as your healthcare provider directs.
Most people take Mavyret for 8 weeks. Treatment may be extended to 12 weeks depending on your HCV genotype, prior treatment history, or presence of cirrhosis. It is a defined, time-limited course aimed at achieving a cure.
Store Mavyret tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor your HCV RNA levels and liver function tests to track your response to treatment. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Mavyret (glecaprevir/pibrentasvir) may help people with chronic hepatitis C achieve sustained virologic response (SVR), or cure, by blocking viral replication at multiple stages. Its pan-genotypic activity means it works against HCV genotypes 1 through 6, and most people complete treatment in as little as 8 weeks with a simple, once-daily oral regimen. Because it is interferon-free and ribavirin-free, Mavyret avoids many of the side effects associated with older hepatitis C therapies. The extent of these benefits varies from person to person, depending on genotype, liver condition, and prior treatment history. Mavyret works best alongside liver-protective lifestyle measures, such as avoiding alcohol and maintaining a balanced diet, and regular monitoring, such as HCV RNA levels and Liver Function Tests (LFTs).
As with any medication, Mavyret may cause side effects, ranging from mild symptoms such as fatigue and headache to less common reactions such as elevated bilirubin. Your healthcare provider will monitor your liver function throughout treatment and assess whether Mavyret remains a suitable option for you.
BENEFITS
Mavyret is approved for HCV genotypes 1 through 6, giving eligible patients a single regimen that works across nearly all forms of hepatitis C.
Most people complete Mavyret treatment in as little as 8 weeks, one of the shortest courses among hepatitis C therapies.
Clinical studies, including the ENDURANCE-1 trial, show Mavyret achieves sustained virologic response (SVR), or cure, in most patients who complete treatment.
Mavyret is taken as tablets once daily with food, offering a straightforward oral regimen without interferon or ribavirin.
These effects are often mild and may improve as treatment continues. Your healthcare provider will discuss the potential benefits and risks before treatment and monitor you throughout the course, including liver function tests, to ensure safe use.
SUPPORTING YOUR CURE
Mavyret works best alongside liver-protective lifestyle measures, such as avoiding alcohol, maintaining a balanced diet, staying hydrated, and managing other conditions that affect liver health.
After completing treatment and achieving cure, avoiding behaviors that could lead to reinfection helps protect the progress your liver has made.
Areas that may support treatment:
COMMON QUESTIONS
Yes, for most patients. Glecaprevir/Pibrentasvir (Mavyret) helps most people reach sustained virologic response (SVR), meaning hepatitis C becomes undetectable in the blood and stays undetectable after treatment ends. SVR is considered a cure. Results vary by genotype, prior treatment history, and whether cirrhosis is present. Your healthcare provider will confirm your response with follow-up blood testing and can explain what a cure means for your specific case.
Most people take Mavyret for 8 weeks. Your healthcare provider may extend Glecaprevir/Pibrentasvir treatment to 12 weeks depending on your HCV genotype, whether you have cirrhosis, or if you have been treated for hepatitis C before. Treatment is a defined, time-limited course rather than an ongoing medication. Discuss your expected treatment length with a healthcare professional, since it is set individually based on your test results and liver condition.
Yes. Chronic hepatitis C can lead to cirrhosis, and cirrhosis is a leading cause of liver tumors, including hepatocellular carcinoma. By helping most patients reach sustained virologic response, Mavyret removes the ongoing viral inflammation that drives this damage over time. Curing hepatitis C does not eliminate all future risk, especially once cirrhosis has developed, so continued monitoring still matters. Ask your healthcare professional about an appropriate liver cancer screening schedule for your situation.
Talk with your healthcare provider before combining any medication with Glecaprevir/Pibrentasvir (Mavyret). Some drugs interact with Mavyret and can affect how well it works or increase side effects, so your provider will review your full medication list, including over-the-counter drugs and supplements, before you start. Do not stop or add medications during treatment without medical guidance. A full review helps your healthcare professional ensure Mavyret works safely and effectively for you.
Mavyret may not be appropriate for people with clinically decompensated liver cirrhosis, significant alcohol or drug use, certain autoimmune diseases, or those who are pregnant or wish to become pregnant. Your healthcare provider will also check for interactions with your current medications before prescribing Glecaprevir/Pibrentasvir. Because eligibility depends on your full health history, only a qualified healthcare professional can determine whether Mavyret is a safe choice for you.
The most common side effects reported are fatigue, headache, nausea, and diarrhea. Elevated bilirubin is a rare side effect of Glecaprevir/Pibrentasvir. Most side effects are mild and may improve as treatment continues. Your healthcare provider will monitor your liver function throughout the course and can help you manage any symptoms that arise. Contact your healthcare professional if side effects are severe, persistent, or concerning.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
